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MR spectroscopic Imaging of peripheral Zone in prostate 
cancer Using a 3T MRI scanner: endorectal versus external 
phased Array coils
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Abstract: Magnetic resonance spectroscopic imaging (MRSI) detects alterations in major prostate metabolites, such as citrate (Cit), 
creatine (Cr), and choline (Ch). We evaluated the sensitivity and accuracy of three-dimensional MRSI of prostate using an endorectal 
compared to an external phased array “receive” coil on a 3T MRI scanner. Eighteen patients with prostate cancer (PCa) who under-
went endorectal MR imaging and proton (1H) MRSI were included in this study. Immediately after the endorectal MRSI scan, the PCa 
patients were scanned with the external phased array coil. The endorec tal coil-detected metabolite ratio [(Ch+Cr)/Cit] was significantly 
higher in cancer locations (1.667 ± 0.663) compared to non-cancer locations (0.978 ± 0.420) (P  0.001). Similarly, for the external 
phased array, the ratio was significantly higher in cancer locations (1.070 ± 0.525) compared to non-cancer locations (0.521 ± 0.310) 
(P  0.001). The sensitivity and accuracy of cancer detection were 81% and 78% using the endorectal ‘receive’ coil, and 69% and 75%, 
respectively using the external phased array ‘receive’ coil.
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Introduction
Prostate cancer (PCa) is the most common non-
 cutaneous cancer and second leading cause of cancer 
death in men. In 2012, approximately 241,740 new 
cases and 28,170 PCa-related deaths occurred in the 
United States.1 Magnetic resonance imaging (MRI) has 
been used to evaluate prostate anatomy and prostate 
pathologies for several years. MRI, with its excellent 
soft-tissue differentiation, provides high-resolution 
images of the prostate and surrounding structures. 
Magnetic resonance spectroscopy (MRS) is a power-
ful tool for exploring the cellular chemistry of human 
tissues.2–6 There is a growing body of evidence that 
proton MRS can be used for clinical evaluation of PCa 
and metabolic alterations before and after therapy. 
Magnetic resonance spectroscopic imaging (MRSI) 
can be used to measure metabolite levels in the tissue, 
particularly choline (Ch), citrate (Cit), creatine (Cr), 
and various polyamines (spermine, spermidine, and 
putrecine). PCa typically shows an increased concen-
tration of Ch and reduction of Cit and polyamines.
MRSI of the prostate is typically performed using a 
combination of point-resolved spectroscopy (PRESS)7 
and three-dimensional localized MRSI8 rather than 
the traditional single-voxel or slice-based two-dimen-
sional MRSI technique was used in brain spectro-
scopic imaging. 3D MRSI requires phase encoding 
along the three spatial dimensions, conventionally 
known as frequency, phase, and slice. Acquisition 
time and coverage of the prostate are the primary con-
siderations in choosing matrix  dimensions. Acquiring 
3D MRSI data with higher spatial resolution requires 
a long total acquisition time.  Conventional prostate 
MRSI studies involving average weighted encoding 
use a long echo time (TE) with a short repetition time 
(TR), allowing observation of a reduced number of 
metabolites.9 Long TEs are used for 3D MRSI due 
to the addition of MEGA10 radio-frequency pulses 
for both water and lipid  suppression. The interpreta-
tion system most used to discriminate between cancer 
and normal prostatic tissue in the peripheral zone was 
described by Kurhanewicz et al.9 They calculated the 
peak area ratios of Ch and Cr to Cit [(Ch+Cr)/Cit] for 
each voxel. Inclusion of Cr in this ratio is mandatory 
because of the Cr peak is very close to the Ch peak in 
the spectrum. However, Cr appears be maintained at 
a relatively constant level in both healthy and tumor 
prostatic tissues.
It was unknown whether the quality of endorectal 
MRSI scanning could be improved by using a stron-
ger (3T) scanner and/or using perfluorocarbon (PFC) 
in the endorectal coil (ERC) instead of air. Rather 
than filling air, PFC has been shown to improve 
MRSI image quality and the magnetic susceptibil-
ity closely matching that of prostate.11 The ERC is 
contraindicated in a number of patients (eg, after 
abdominal perineal resection for rectal cancers or 
after radiation therapy for the pelvis).12 In some cases, 
it is preferable to not use an ERC to avoid structural 
deformation of the prostate peripheral zone, which is 
often compressed by an ERC. The ERC also causes 
signal hyperintensity near the rectum and the neigh-
boring peripheral zone. Signal hyperintensity and 
tissue deformation can make complicate diagnostic 
 interpretation. Previous studies have reported the use 
of external phased array coils for prostate MR spec-
troscopy in 3T.13–20 The major goal of the study was to 
evaluate 3T MRSI for the peripheral zone in prostate 
cancer patients using an endorectal coil and to com-
pare the performance of 3T MRSI and an external 
phased array ‘receive’ coil.
Materials and Methods
Eighteen patients ranging in age from 56–72 years 
(mean, 63.1 years) with PCa who underwent endorec-
tal MR imaging and proton MR spectroscopic imag-
ing were included in this study. The study protocol 
was approved by the Institutional Review Board, and 
informed consent was obtained from each patient. 
Gleason scores for the tumor on prostate biopsy 
ranged from 3 to 8, while prostate-specific antigen 
varied from 2.8 to 20.6 ng/mL (mean of 6.84 ng/mL). 
A Siemens 3T MRI Scanner with high-performance 
gradients (Trio-Tim, Siemens Medical Solutions, 
Erlangen, Germany) was used in this investigation. 
A quadrature body ‘transmit’ coil was used to trans-
mit radio-frequency pulses. An endorectal inflatable 
‘receive’ coil (Medrad Corporation, Indianola, PA, 
USA) was then inserted into the rectum and inflated 
with 50 cc PFC. The coil was positioned horizon-
tally at approximately the 10:00 and 2:00 positions. 
After endorectal scanning, patients were scanned with 
the external phased array ‘receive’ coil for the com-
parison study. T2-weighted images in the transverse, 
sagittal, and coronal planes were acquired by using a 
turbo spin-echo sequence. The MRI protocol included 
MRSI of prostate cancer using endorectal and external coils
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T2-weighted images acquired using a fast spin-echo 
sequence with: repetition time (TR) = 3,800 ms, 
effective echo time (TE) = 101 ms, slice thick-
ness = 3 mm, field of view = 140 mm, and matrix 
size = 256 × 256 mm2. MRSI was performed in all 
patients, which included a 3D water- and fat-suppressed 
spectroscopic  acquisition. 3D MRSI parameters of the 
endorectal and external phased array coil were as fol-
lows: TR 750 ms, TE 145 ms, acquisition bandwidth 
1250 Hz, 6 averages, and 512 spectral data points with 
a voxel resolution of 0.3 mL. Total acquisition time 
was approximately 12 min. For the external phased 
array, the voxel resolution was 0.35 mL. A PRESS-
based sequence was used to acquire proton MR spec-
tra from a volume of interest (VOI) of approximately 
55 × 45 × 45 mm3. Outer volume suppression of water 
and lipid was achieved using eight 3-cm thick satura-
tion pulses around the VOI.
A spectroscopist examined the MRSI data set 
and reported the location and number of suspicious 
voxels to the radiologist, to identify metabolite 
ratios predictive of cancer. For 3D MRSI post-pro-
cessing, each spectrum was Fourier transformed, 
frequency-, phase-, and baseline-corrected, and the 
peaks of Cit, Ch, and Cr were subsequently fitted. 
A Hamming filter was used for the MRSI spatial 
dimensions of the data. For tumor localization, the 
prostate was split along the midline and further 
divided into the apex, the middle, and the base of 
the gland. According to histopathologic findings, 
the voxels and corresponding spectra were assigned 
as normal tissue or tumor tissue. For selected vox-
els in the peripheral zone, the area under the curve 
of the metabolite resonances was determined and 
the signal intensity ratio for (Ch+Cr)/Cit was calcu-
lated using commercially available software from 
Siemens. Peak areas for Ch, Cr, Spm, and Cit were 
calculated using numeric integration.  Metabolic 
maps of (Ch+Cr)/Cit were generated since Spm 
cannot be separated from Ch and Cr peaks.  Voxels 
were considered suitable if they consisted of at least 
75% peripheral zone tissue and did not include peri-
urethral tissue. If the Cit peak was lower than the 
Ch peak or was undetectable, the voxel was deter-
mined to be malignant. If the Cit peak was higher 
than the Ch peak, the voxel was considered noncan-
cerous for (Ch+Cr)/Cit values smaller than 0.50 and 
malignant for (Ch+Cr)/Cit values greater than 0.50. 
For the external phased array coil, the noncancer-
ous ratio was less than 0.28 and the malignant ratio 
was greater than 0.28.
The paired t-test was used to determine whether 
the ratios of (Ch+Cr)/Cit in cancer were different 
from those in non-cancer using an endorectal coil and 
external coil. A P-value less than 0.05 was considered 
statistically significant.
Receiver operating characteristic (ROC) curve 
analyses based on logistic regression models were 
performed to identify the optimal cutoff value for pre-
dicting metabolite ratios using the endorectal coil and 
external phased array coil. The area under the curve 
(AUC), interpreted as the average value of sensitiv-
ity for all possible values of specificity, was used in 
the ROC analysis. An area of 0.50 implies that the 
variable adds no information, whereas an area of 1 
implies perfect accuracy. Sensitivity, specificity, posi-
tive predictive value (PPV), and negative predictive 
value (NPV) as well as accuracy were reported for the 
optimal thresholds. P-values  0.05 were considered 
statistically significant. Statistical analyses were per-
formed using SPSS software (Statistical Package for 
the Social Sciences, Version 18.0, SPSS Inc,  Chicago, 
IL, USA).
Results
Figure 1A and B show the metabolite ratios (Ch+Cr)/
Cit for cancer and non-cancer locations with 
endorectal and external phased array coil in 18 PCa 
patients. For the endorectal coil, the metabolite ratio 
(mean ± SD) was significantly higher in cancer loca-
tions (1.667 ± 0.663) compared to in non-cancer loca-
tions (0.978 ± 0.420) (P  0.001). Similarly, for the 
external phased array coil, the ratio was significantly 
higher in cancer locations (1.070 ± 0.525) than in 
non-cancer locations (0.521 ± 0.310) (P  0.001). 
Figure 2A and B show a comparison of endorectal 
and external phased array MR Spectroscopic Imag-
ing of a 67 year-old PCa patient. A significant eleva-
tion in Ch/Cr and decreased Cit were observed in the 
right side peripheral zone of the PCa patient scanned 
using endorectal coil. Similar trends for metabolite 
changes are shown in Figure 2B with a slightly worse 
signal-to-noise ratio (SNR) because the patient was 
scanned using an external coil. Table 1 shows the full 
width at half maximum (FWHM) of Cit and (Cr+Ch) 
in cancer and noncancerous locations using the 
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Figure 1. Comparison of metabolite ratios [(Ch+Cr)/Cit] in 18 PCa patients scanned with the endorectal and external body array ‘receive’ coils.
note: Significant (P  0.05) elevation of Ch/Cr observed in cancer locations compared to non-cancer locations in both coils.
endorectal and external phased array coil. The mean 
FWHM of Cit in cancer and non-cancer locations for 
patients scanned using the endorectal coil were 11.7 
and 11.5 Hz respectively, whereas using the external 
coil, the mean FWHM values were 17.7 and 19.5 Hz, 
which showed a higher coefficient of variance (CV). 
Similarly, the mean FWHM of Ch+Cr in cancer and 
non-cancer locations of patients scanned using the 
endorectal coil were 17.7 and 19.5 Hz, where in the 
external coil, the mean FWHM values were 25.7 and 
28 Hz with a higher CV. The mean global water line 
width of 25 Hz observed using the endorectal coil and 
31 Hz was observed using the external phased array 
coil with higher CV.
Figure 3 shows that the MRSI metabolite ratios 
in peripheral zone cancer locations derived from 
endorectal coil- and external body coil were positively 
and linearly correlated (R2 = 0.571). Figure 4 shows 
the comparison of receiver operating characteristics 
curves for the endorectal coil- and external body coil-
derived MRSI ratio. ROC curve analyses for differ-
entiating endorectal coil suggested an optimal cutoff 
value of 1.35. This implies that the proportions of cor-
rectly identified endorectal coil  sensitivity,  specificity, 
MRSI of prostate cancer using endorectal and external coils
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Figure 2. Comparison of (A) endorectal and (B) external body array MR Spectroscopic Imaging of a 67-year old PCa patient.
note: Extracted single voxel spectra show a significant (P  0.05) elevation of Ch/Cr and declined Cit in the right side peripheral zone of the PCa patient 
in both coils.
Table 1. FWhM of water and metabolite resonances using endorectal and external body array “receive” coils. 
peak endorectal FWHM  
Mean ± sD
cV (%) external body array FWHM  
Mean ± sD
cV (%)
Cancer Cit 11.73 ± 2.75 23.41 15.45 ± 6.17 39.96
Cancer (Cr+Ch) 17.71 ± 6.78 27.57 25.75 ± 8.47 32.88
Non-cancer Cit 11.53 ± 1.73 15.02 18.83 ± 10.16 53.94
Non-cancer (Cr+Ch) 19.59 ± 6.83 27.77 28.06 ± 10.80 38.49
Water 25.00 ± 5.16 20.64 31.00 ± 9.62 31.05
note: The FWhM of the water resonance represents global line width whereas the FWhM values of metabolites were derived from spectra extracted from 
selected locations.
PPV, and NPV were 81.3%, 75.0%, 76.5%, and 80.0%, 
respectively. The AUC was 86.9%, with an accuracy 
of 78.1%. The cutoff value for the external body coil 
was 0.77 for sensitivity, specificity, and accuracy 
values of 68.8%, 81.3%, and 75.0%,  respectively. 
The AUC of the MRSI ratio slightly increased for 
endorectal coil (86.9%) compared to external phased 
array coil (85.9%). In the evaluation of the endorec-
tal coil versus external phased array coil, the MRSI 
ratios showed an accuracy of 78.1%, indicating good 
discrimination compared to external phased array of 
75.0%. Detailed results of the ROC curve analyses 
are shown in Table 2, which shows the sensitivity, 
specificity, PPV, NPV, AUC, and accuracy of classi-
fying endorectal coil and external body coil.
Discussion
Numerous studies have suggested that MRSI using 
an ERC is the most promising technique for detect-
ing and staging of PCa. At more commonly available 
clinical field strengths of 1.5T, an ERC is necessary 
for obtaining a sufficiently high SNR with subsequent 
spatial resolution, allowing reliable cancer delineation 
in a clinically reasonable time frame. However, the 
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External phased array coil
Figure 3. Correlation between the maximum ratios [(Ch+Cr)/Cit] of can-
cer identified in the peripheral zone with external phased array coil vs. 
endorectal coil MRS.





























Figure 4. ROC curves of MRSI ratios of prostate cancer patients (A) with the endorectal and (B) the external phased array ‘receive’ coils.
use of an ERC is more time-consuming, leading to 
higher costs and greater patient discomfort. Thus, we 
compared the performance of the endorectal coil with 
the external phased array coil at 3T.
Compared with external phased array coil at 3T, 
endorectal MR spectroscopy at 3T significantly 
improves spectral line width and coefficient of vari-
ance of metabolite ratio. The FWHM is a good indi-
cator of spectral homogeneity. The FWHM value 
typically increases as VOI increases. Excellent quality 
of prostate spectra can be obtained through optimiza-
tion of B0 homogeneity for the PRESS-selected VOI. 
This procedure typically involves the combined use 
of a standard automatic shim provided by the man-
ufacturer and, if necessary, manual adjustments of 
the linear x, y, and z gradients. Small improvements 
in shim can make a significant difference in spectra 
quality. Particularly, good B0 homogeneity is  essential 
for sufficient water and lipid suppression. Water and 
lipid suppression is achieved through generation of 
frequency-selective MEGA pulses.10 During MRSI 
acquisition, large lipid resonance peaks obscures the 
metabolite peak. Outer volume saturation pulses were 
used to eliminate signals from adjacent tissues, par-
ticularly periprostatic lipids and rectal wall tissue. 
The coefficient of variance was higher in the external 
phased array than for the endorectal coil due to the 
larger size of the coil and increased distance from the 
prostate proportional to abdominal circumference, 
leading to a decrease in the SNR ratio.
The overall accuracy of the external phased array 
coil MRSI has been shown to be slightly inferior to 
that using the endorectal coil in our pilot study involv-
ing a limited number of patients. In the localization of 
PCa with MRSI at 3T, the use of the endorectal coil 
showed a significantly (P  0.05) higher sensitivity 
(81.3%) than the external phased array (68.8%). In 
contrast, the specificities of cancer detection were 
81% and 75% using the external phased array and the 
endorectal coils, respectively. Additionally, there was 
a slight increase in the AUC (86.9%) for endorec-
tal compared to the external phased array AUC 
(85.9%).
In our investigations using an external phased 
array coil, the effective voxel size was slightly 
larger to compensate for the poor SNR compared 
to examinations of the prostate using an endorectal 
coil.  Overlap exists in the (Ch+Cr)/Cit ratios between 
cancer and noncancerous tissues. For both ERC and 
external phased array coils, (Ch+Cr)/Cit ratios were 
significantly higher in cancer locations than non-
cancer locations in this study, in accordance with the 
MRSI of prostate cancer using endorectal and external coils
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results of previous studies.21–30 Additionally, the trend 
of accuracy and sensitivity of the ERC in this study 
agreed with that of a previous study.20 The metabo-
lite mean ratio of the external phased array coil was 
lower in cancer and non-cancer locations due to the 
low SNR. However, the ratio of (Ch+Cr)/Cit using 
both coils was generally positively and linearly cor-
related. Although AUC and sensitivity were elevated 
for ERC, the results imply that both ERC and exter-
nal phased-array coil MRS are feasible for detecting 
the peripheral zone cancer with an optimal threshold 
ratio for (Ch+Cr)/Cit.
Although the sensitivity and accuracy increased 
in ERC, there are some disadvantages of using this 
method. Disadvantages of using an ERC include its 
invasiveness, image distortions, and a limited field 
of view. The accuracy of endorectal coil MRI is also 
frequently affected by image degradation. The three 
most common causes of this are near-field endorectal 
surface coil profile (because the coil is close to the 
gland), phase encoding artifact (from motion of feces 
or the rectum itself), and incorrect placement of the 
coil (where the coil is not parallel to the transverse 
plane of the gland).31
Another limitation is the small number of patients 
in this study. Additionally, there was no correlation 
between Gleason scores and MRSI ratios. Another 
limitation of this study was the inclusion of only the 
peripheral zone of the prostate, in which 75% cancer 
arises.
conclusion
These preliminary findings confirmed that the use 
of ERC significantly improves spectral line width 
and the coefficient of variance of metabolite ratio 
compared with the external phased array coil. 
However, based on overall performance, use of the 
external phased array coil may be recommended for 
patients with rectal diseases or patients who could 
not tolerate the discomfort of endorectal surface 
coil insertion.
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